Posted 29th March 2019 by Joshua Broomfield
Günter Welz is part of the Open Innovation and Strategic Partnerships department at Bayer. He scouts for and builds relationships with external innovators in academia and business to enrich Bayer’s R&D pipeline, using various tools like the Open Innovation website and the venture capital arm.
A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD
Posted 27th March 2019 by Joshua Broomfield
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.
Posted 25th March 2019 by Joshua Broomfield
This is the first instalment of a two-part blog post from Jothi Dugar, one of the pioneers in the field of Cyber Security. Here, Jothi shares her experience of Cyber Security and developing an Information Security Office in a healthcare setting.
Posted 22nd March 2019 by Joshua Broomfield
As laboratories transform their workflows into the digital environment, a tremendous opportunity presents itself: to transition the field of pathology from a qualitative to quantitative discipline. Quantitation brings measures of accuracy, reproducibility, and statistical stringency that allow computational algorithms (including AI) to perform complex tasks and measure their success. The evolution of Pathology will not be dictated by any single organization but rather will take an entire community of experts.
Posted 20th March 2019 by Joshua Broomfield
The Human Genome Project was the largest collaborative scientific project that is credited with transforming our understanding of human genetics and revolutionizing medical research. It’s completion in 2003 was greeted as a watershed moment in the history of scientific discovery.
Today, a much less heralded collaborative scientific project is underway that may have implications for human health that could be as profound as that of the Human Genome Project. The Human Microbiome Project (HMP) is a National Institutes of Health (NIH)-supported collaboration that develops “research resources to enable the study of the microbial communities that live in and on our bodies and the roles they play in human health and disease”.
Posted 18th March 2019 by Joshua Broomfield
Regulation of emerging technology such as genome editing has mainly focused on responding to the consequences of innovation. The classical regulatory model of “identification-quantification-assessment-safety management” takes a risk-oriented approach to regulation of emerging technology and focuses on constraining the practice of science based on ethics, and administrative and risk management procedures.
Posted 15th March 2019 by Joshua Broomfield
For over a decade, Memorial Sloan Kettering has implemented digital pathology enterprise system for clinical scanning. Over the years that has evolved significantly. Currently, a lot of our efforts are spent on archive scanning to be available for prospective clinical cases.
Efforts to enable pathologists the ability for primary diagnosis are being explored, and we’re currently validating available systems. There’s always a certain flux in terms of vendor communication and networking, meaning that we’re validating systems for our internal use whether that’s for clinical, education, or research.
Posted 13th March 2019 by Joshua Broomfield
The BioMillenia technology platform is based on microfluidics, a technology platform widely used in life sciences, but not necessarily in microbiology. There are some commercial developments of the technology, for example NGS or dPCR platforms, but it’s a very new application in the field of microbiology.